Skip to main content

20.11.2023 | original report

Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study

verfasst von: Yu Fu, Long Su, Yuying Li, Yehui Tan

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten

Summary

Purpose

To analyze the effectiveness of decitabine combined with low-dose Ara‑C, aclarubicin, and rhG-CSF (DCAG) as a salvage therapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).

Patients and methods

This single-centered retrospective study included patients with relapsed/refractory AML between January 2013 and June 2020. The response rate and survival were calculated, and their correlations with clinical characteristics were estimated.

Results

Thirty-seven patients were enrolled. The overall response rate (ORR) was 56.8% with a complete remission (CR) rate of 51.4%. For patients with non-refractory and refractory AML, the CR rates were 87.5% and 30.4%, respectively (p < 0.001). No remission was found in four primary refractory AML. The incidence of infections was 73%, wherein 13.5% had severe infection, and 2.7% with treatment-related mortality. The median overall survival (OS) and relapse-free survival (RFS) were 10.6 (7.7–13.5) months and 5.0 (2.8–7.2) months, respectively. Patients in the poor risk category had a shorter OS (P = 0.004). The OS and RFS of patients with a recurrence time of < 6 months were shorter (P = 0.018 and P < 0.001, respectively).

Conclusions

The DCAG regimen was an effective and well-tolerated therapeutic alternative for R/R AML, particularly in non-refractory patients. Patients in the poor risk category and early relapse were adverse factors for remission rate and survival.
Literatur
1.
Zurück zum Zitat Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. CrossRefPubMedPubMedCentral Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Walter RB, Othus M, Brunett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI,HOVON/SAKK,SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312–20. CrossRefPubMed Walter RB, Othus M, Brunett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI,HOVON/SAKK,SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312–20. CrossRefPubMed
3.
Zurück zum Zitat Cui L, Liu Y, Pang Y, et al. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Ther. 2020;27(1-2):1–14. CrossRef Cui L, Liu Y, Pang Y, et al. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Ther. 2020;27(1-2):1–14. CrossRef
4.
Zurück zum Zitat Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018;93(8):1074–81. CrossRefPubMedPubMedCentral Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018;93(8):1074–81. CrossRefPubMedPubMedCentral
5.
6.
Zurück zum Zitat Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012;26(2):244–54. CrossRefPubMed Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia. 2012;26(2):244–54. CrossRefPubMed
7.
Zurück zum Zitat Jiang X, Wang Z, Ding B, et al. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015;6(32):33612–22. CrossRefPubMedPubMedCentral Jiang X, Wang Z, Ding B, et al. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget. 2015;6(32):33612–22. CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol. 2012;91(12):1879–86. CrossRefPubMed Song LX, Xu L, Li X, et al. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia. Ann Hematol. 2012;91(12):1879–86. CrossRefPubMed
9.
Zurück zum Zitat Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97(7):1115–53. CrossRefPubMed Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018;97(7):1115–53. CrossRefPubMed
10.
Zurück zum Zitat Tiong IS, Wei AH. New drugs creating challenges in acute myeloid leukemia. Genes Chromosomes. Cancer. 2019;58(12):903–14. Tiong IS, Wei AH. New drugs creating challenges in acute myeloid leukemia. Genes Chromosomes. Cancer. 2019;58(12):903–14.
12.
Zurück zum Zitat Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47–55. CrossRefPubMed Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47–55. CrossRefPubMed
13.
Zurück zum Zitat Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML:outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923–32. CrossRefPubMedPubMedCentral Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML:outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923–32. CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):2003–7. CrossRefPubMed Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9):2003–7. CrossRefPubMed
15.
Zurück zum Zitat Lee SR, Yang DH, Ahn JS, et al. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. J Korean Med Sci.2009;24(3):498–503. Lee SR, Yang DH, Ahn JS, et al. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. J Korean Med Sci.2009;24(3):498–503.
16.
Zurück zum Zitat Wang LJ, Ding J, Zhu CY, et al. Clinic outcome of FLAG regimen treating patients with refractory and relapse acute myeloid leukemia. J Exp Hematol. 2016;24(1):19–24. Wang LJ, Ding J, Zhu CY, et al. Clinic outcome of FLAG regimen treating patients with refractory and relapse acute myeloid leukemia. J Exp Hematol. 2016;24(1):19–24.
17.
Zurück zum Zitat Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9(4):298–301. CrossRefPubMed Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9(4):298–301. CrossRefPubMed
18.
Zurück zum Zitat Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011;35(3):301–4. CrossRefPubMed Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011;35(3):301–4. CrossRefPubMed
19.
Zurück zum Zitat Trifilio SM, Rademaker AW, Newman D, et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res. 2012;36(4):394–6. CrossRefPubMed Trifilio SM, Rademaker AW, Newman D, et al. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res. 2012;36(4):394–6. CrossRefPubMed
20.
Zurück zum Zitat Kohrt HE, Patel S, Ho M, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010;85(11):877–81. CrossRefPubMed Kohrt HE, Patel S, Ho M, et al. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Am J Hematol. 2010;85(11):877–81. CrossRefPubMed
21.
Zurück zum Zitat Fan CH, Yu MJ, Mai MY, et al. Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia. Chin J Hematol. 2016;37(2):100–4. Fan CH, Yu MJ, Mai MY, et al. Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia. Chin J Hematol. 2016;37(2):100–4.
22.
Zurück zum Zitat Li L, Zhang X, Yu H, et al. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations. Onco Targets Ther. 2018;11:6863–70. CrossRefPubMedPubMedCentral Li L, Zhang X, Yu H, et al. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations. Onco Targets Ther. 2018;11:6863–70. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Chen Y, Dai M, Liu Q. Efficacy and safety of DAC combined with CAG regimen (decitabine in combined with aclacinomycin, cytarabine and G‑CSF) as a second induction regimen compared with Non-DAC regimen for acute myeloid leukemia who failed the first course of standard induction IA chemotherapy. Blood. 2019;134((sup1):5104–5104. CrossRef Chen Y, Dai M, Liu Q. Efficacy and safety of DAC combined with CAG regimen (decitabine in combined with aclacinomycin, cytarabine and G‑CSF) as a second induction regimen compared with Non-DAC regimen for acute myeloid leukemia who failed the first course of standard induction IA chemotherapy. Blood. 2019;134((sup1):5104–5104. CrossRef
24.
Zurück zum Zitat Wang L, Luo J, Chen G, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenetics. 2020;12(1):132. CrossRef Wang L, Luo J, Chen G, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenetics. 2020;12(1):132. CrossRef
25.
Zurück zum Zitat Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484–91. CrossRefPubMed Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484–91. CrossRefPubMed
26.
Zurück zum Zitat Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019;32(2):134–44. CrossRefPubMed Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol. 2019;32(2):134–44. CrossRefPubMed
27.
Zurück zum Zitat Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–21. CrossRefPubMed Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–21. CrossRefPubMed
28.
Zurück zum Zitat Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5(7):e331. CrossRefPubMedPubMedCentral Hou HA, Chou WC, Kuo YY, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5(7):e331. CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016;375(21):2023–36. CrossRefPubMed Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016;375(21):2023–36. CrossRefPubMed
Metadaten
Titel
Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study
verfasst von
Yu Fu
Long Su
Yuying Li
Yehui Tan
Publikationsdatum
20.11.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00933-x